Bruker Corporation

NasdaqGS:BRKR Stock Report

Market Cap: US$8.4b

Bruker Valuation

Is BRKR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BRKR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BRKR ($57) is trading above our estimate of fair value ($2.5)

Significantly Below Fair Value: BRKR is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BRKR?

Key metric: As BRKR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BRKR. This is calculated by dividing BRKR's market cap by their current earnings.
What is BRKR's PE Ratio?
PE Ratio28.3x
EarningsUS$304.90m
Market CapUS$8.38b

Price to Earnings Ratio vs Peers

How does BRKR's PE Ratio compare to its peers?

The above table shows the PE ratio for BRKR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.9x
CRL Charles River Laboratories International
23x12.1%US$9.3b
STVN Stevanato Group
46.9x20.0%US$5.8b
TECH Bio-Techne
77.2x21.2%US$11.3b
MEDP Medpace Holdings
28.6x10.8%US$10.4b
BRKR Bruker
28.3x15.8%US$8.4b

Price-To-Earnings vs Peers: BRKR is good value based on its Price-To-Earnings Ratio (28.3x) compared to the peer average (43.9x).

Price to Earnings Ratio vs Industry

How does BRKR's PE Ratio compare vs other companies in the US Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
REPC.F RepliCel Life Sciences
0.3xn/aUS$123.50k
No more companies available in this PE range
BRKR 28.3xIndustry Avg. 35.7xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BRKR is good value based on its Price-To-Earnings Ratio (28.3x) compared to the Global Life Sciences industry average (35.7x).

Price to Earnings Ratio vs Fair Ratio

What is BRKR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BRKR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.3x
Fair PE Ratio26.4x

Price-To-Earnings vs Fair Ratio: BRKR is expensive based on its Price-To-Earnings Ratio (28.3x) compared to the estimated Fair Price-To-Earnings Ratio (26.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BRKR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$57.00
US$73.80
+29.5%
9.5%US$85.00US$60.00n/a13
Dec ’25US$57.95
US$74.74
+29.0%
9.4%US$85.00US$60.00n/a11
Nov ’25US$59.29
US$78.28
+32.0%
10.3%US$90.00US$60.00n/a11
Oct ’25US$66.76
US$79.51
+19.1%
10.6%US$90.00US$60.00n/a10
Sep ’25US$67.19
US$79.74
+18.7%
10.1%US$90.00US$60.00n/a11
Aug ’25US$68.33
US$80.91
+18.4%
10.8%US$90.00US$60.00n/a10
Jul ’25US$62.33
US$84.21
+35.1%
8.0%US$95.00US$72.00n/a10
Jun ’25US$65.51
US$83.23
+27.0%
9.5%US$95.00US$72.00n/a9
May ’25US$79.03
US$89.40
+13.1%
11.2%US$105.00US$73.03n/a10
Apr ’25US$92.93
US$84.40
-9.2%
10.7%US$95.00US$66.00n/a10
Mar ’25US$88.33
US$86.00
-2.6%
11.6%US$102.00US$66.00n/a11
Feb ’25US$72.58
US$74.37
+2.5%
13.2%US$86.00US$58.00n/a11
Jan ’25US$73.48
US$72.09
-1.9%
12.7%US$86.00US$57.00n/a12
Dec ’24US$66.06
US$70.56
+6.8%
13.9%US$86.00US$57.00US$57.959
Nov ’24US$57.01
US$79.22
+39.0%
14.8%US$95.00US$59.00US$59.299
Oct ’24US$62.30
US$83.33
+33.8%
11.6%US$95.00US$68.00US$66.769
Sep ’24US$65.94
US$83.33
+26.4%
11.6%US$95.00US$68.00US$67.199
Aug ’24US$70.17
US$88.56
+26.2%
8.6%US$98.00US$73.00US$68.339
Jul ’24US$73.92
US$88.78
+20.1%
8.7%US$98.00US$73.00US$62.339
Jun ’24US$70.94
US$88.00
+24.0%
9.5%US$98.00US$73.00US$65.519
May ’24US$78.55
US$82.44
+5.0%
10.3%US$92.00US$68.00US$79.039
Apr ’24US$78.84
US$79.00
+0.2%
11.0%US$90.00US$63.00US$92.939
Mar ’24US$67.46
US$79.00
+17.1%
11.0%US$90.00US$63.00US$88.339
Feb ’24US$71.36
US$74.00
+3.7%
9.5%US$82.00US$59.00US$72.589
Jan ’24US$68.35
US$72.11
+5.5%
9.4%US$80.00US$56.00US$73.489
Dec ’23US$67.68
US$72.11
+6.5%
9.4%US$80.00US$56.00US$66.069

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 22:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bruker Corporation is covered by 35 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Michael RyskinBofA Global Research
Derik de BruinBofA Global Research